Daratumumab ( Darzalex (subcutaneous and intravenous formulations), Darzalex Faspro (subcutaneous formulation with hyaluronidase) )

Immunotherapy

EMA Approved

Hospital use 1 Clinical Trials

Description

Daratumumab is primarily used in the treatment of multiple myeloma and has shown promise in clinical trials for other hematologic malignancies. Its use in colorectal cancer is investigational, with ongoing studies exploring its potential as a therapeutic agent in combination with standard chemotherapy or targeted therapies.

Mechanism of Action

Daratumumab is a human IgG kappa monoclonal antibody that specifically binds to CD38, an antigen highly expressed on multiple myeloma cells and some solid tumors including colorectal cancer; it induces cell death by apoptosis and complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC).

Side Effects

Neutropenia; infusion-related reactions; thrombocytopenia; anemia; upper respiratory tract infections; diarrhea; constipation; nausea; peripheral edema; cough; fatigue; pyrexia; musculoskeletal pain

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT02060188 Phase 2

Completed

A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread

United States, Australia, Belgium, Canada, France, Ireland, Italy, Spain

Quick Info

Brand Name	Darzalex (subcutaneous and intravenous formulations), Darzalex Faspro (subcutaneous formulation with hyaluronidase)
Category	Immunotherapy
EMA Status	EMA Approved
Spain Access	Hospital use
Clinical Trials	1

View Clinical Trials Back to Drug Glossary

Related Medications

Medical Disclaimer

This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.

Daratumumab (** Darzalex (subcutaneous and intravenous formulations), Darzalex Faspro (subcutaneous formulation with hyaluronidase) **)